Company intelligence / Profile preview

Liveome

Suwon-si, Gyeonggi-do, South Koreain.marketscreener.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Liveome has completed a Phase 1 clinical trial in Australia for its gene-recombinant microbiome drug, LIV001, targeting IBD. Preclinical studies have confirmed efficacy in acute and chronic enteritis. The company is expanding its pipeline to include anticancer candidates.[4][5]

Therapeutic areas: GastroenterologyOncology
Modalities: Live biotherapeutic products (LBPs)Gene-recombinant microbiome therapeuticsMicrobial cell therapies[4][5][6]
Industry: Biotech

Drug pipeline

6 assets

LIV001

5 more assets in the full pipeline.

Request access →

Partnerships

Luina Bio (Australia): CDMO partner supplying raw materials for clinical manufacturing of LBPs [5]Quay Pharma / SGS Quay Pharma UK : CDMO partner responsible for finished product manufacturing and formulation development [5][6]

Beyond the preview

Go deeper on Liveome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Liveome.

Explore the full profile